DGAP-News

Sangui BioTech: Sales of USD 37,005 in the first nine months

DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter Results
Sangui BioTech: Sales of USD 37,005 in the first nine months

06.06.2016 / 10:10
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Sangui BioTech: Sales of USD 37,005 in the first nine months

- Cost cutting program is effective: cost reduction by 60%
- Reimbursment Commitments of Granulox in the Netherlands and the Czech
Republic

Witten, Germany, June 6, 2016 -
In the first nine months of fiscal year 2016 (to 31/03/2016) Sangui BioTech
International Inc. achieved revenues from royalty income and product sales
of USD 37,005. In the same period of the previous year the comparable
revenue amounted to USD 116,500.

The cost- cutting- and liability-protection program adopted during the
last quarter shows first success. Thus, the cost of business operations for
the quarter could be reduced by USD 124,376 or 60% to USD 81,626. For the
first three quarters of the fiscal year the cost reduction totaled USD 334
414 or 48%. As a result of this, the operating loss of the quarter
decreased compared to the prior year quarter by USD 88,735 to USD 106,795
respectively for the first nine months from USD 579,088 to USD 365,387.
Accordingly, the cash position of the Company during the reporting period
improved.


After declining royalty income due to lower turnover of the wound
treatment product Granulox in previous quarters, the company expects for
the further development of the fiscal year 2016 and the fiscal year 2017
rising sales of Granulox and accordingly increasing royalty income.

This prediction is supported by successful efforts of the licensee, the
Sastomed GmbH to grant reimbursement commitments for the costs caused by
using Granulox from the relevant health insurance companies.

During the current quarter, the reimbursement of 100 % respectively 75 %
of the costs caused by using Granulox could be reached in the Netherlands
respectively in the Czech Republic. Discussions with the not yet
reimbursing health insurance companies in Germany will continue.

Accessorily SastoMed GmbH was able to acquire a strong and experienced
partner during the quarter for Poland. Negotiations with potential partners
about distribution rights for territories in the South-East Asian region
are in an advanced stage. In addition, the continuously increasing sales
efforts of SastoMed - partners in the already developed territories will
lead to increasing sales figures of Granulox. Here the partners in Mexico
and Peru are mentioned in particular.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Sangui Biotech International, Inc.
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such forward-
looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.


---------------------------------------------------------------------------

06.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

469327 06.06.2016